Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

T2 Biosystems brings in $15mm through its Series C round

Executive Summary

T2 Biosystems Inc. (rapid molecular testing using nanotechnology and miniaturized magnetic resonance) has raised $15mm through its Series C financing led by first-time backer Physic Ventures, which adds a board member. Other new investors Arcus Ventures, RA Capital, Camros Capital, and WS Investments were joined by returning shareholders Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, and Partners Healthcare. The company will use the money for ongoing development and the eventual commercialization of its next-generation diagnostic platform for use in a decentralized setting. T2 Biosystems' October 2008 Series B round generated $10.8mm.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Saliva-based Testing
    • Urine-based Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies